In modern antiviral therapy, Tenofovir Alafenamide 25 mg has emerged as a breakthrough in the treatment of Hepatitis B Virus (HBV) infection and as part of combination therapy for HIV-1 infection. TELAVINCE AF25, manufactured by Steris Healthcare Pvt. Ltd., is a single-tablet formulation containing Tenofovir Alafenamide 25 mg, designed to deliver high intracellular antiviral activity while minimizing systemic exposure, thus reducing potential side effects.
This formulation is particularly suitable for patients seeking effective, safe, and convenient antiviral therapy, offering improved viral suppression, better renal and bone safety, and enhanced quality of life.
Composition
Each tablet of TELAVINCE AF25 contains:
Tenofovir Alafenamide (TAF) – 25 mg
This modern prodrug of Tenofovir is optimized for high intracellular concentration, ensuring potent inhibition of viral replication at lower systemic doses compared to older formulations.
What is TELAVINCE AF25?
TELAVINCE AF25 is a prescription antiviral medication used for:
Chronic Hepatitis B (CHB) in adults and adolescents
Part of combination therapy for HIV-1 infection when prescribed by a healthcare provider
Tenofovir Alafenamide, the active component, is a nucleotide reverse transcriptase inhibitor (NtRTI). It works by blocking viral DNA synthesis, preventing the virus from multiplying and causing further damage to the liver or immune system.
Mechanism of Action
Tenofovir Alafenamide (TAF) is a prodrug of Tenofovir, meaning it is converted into the active form inside infected cells. This approach offers several advantages:
High intracellular concentration: Ensures effective viral suppression at lower doses.
Reduced systemic exposure: Minimizes kidney and bone toxicity compared to Tenofovir Disoproxil Fumarate (TDF).
Inhibition of viral replication: Blocks the enzyme reverse transcriptase, preventing viral RNA from being converted into DNA.
Improved tolerability: Safer long-term therapy with fewer side effects.
This precise mechanism makes TELAVINCE AF25 a potent and safe antiviral solution for long-term viral management.
Uses and Indications
TELAVINCE AF25 is primarily prescribed for:
Treatment of Chronic Hepatitis B (CHB): Reduces viral load and prevents liver damage such as cirrhosis or hepatocellular carcinoma.
Part of HIV-1 therapy: In combination with other antiretrovirals, it helps achieve effective viral suppression.
Long-term viral management: Suitable for patients requiring ongoing antiviral therapy due to chronic infection.
By lowering viral load and supporting immune function, TELAVINCE AF25 improves patient outcomes and slows disease progression.
Key Benefits of TELAVINCE AF25
Potent Antiviral Action: Suppresses HBV and HIV replication effectively.
Improved Safety Profile: Reduced kidney and bone toxicity compared to older Tenofovir formulations.
Convenient Once-Daily Dosing: Enhances adherence and treatment consistency.
Long-Term Tolerability: Safe for extended use under medical supervision.
Supports Combination Therapy: Can be combined with other antiretrovirals for optimal HIV management.
Enhanced Quality of Life: Helps maintain health and activity levels for patients.
Dosage and Administration
Recommended Dose: One tablet once daily, with or without food.
Duration: Continue as prescribed by your healthcare provider; do not skip doses.
Special Considerations: Patients with kidney impairment may require dosage adjustments.
Always follow your physician’s instructions for optimal results and safety.
Possible Side Effects
TELAVINCE AF25 is generally well tolerated, but some patients may experience:
Common Side Effects:
Nausea or vomiting
Headache or fatigue
Abdominal discomfort
Mild dizziness
Serious Side Effects (rare):
Kidney function changes (elevated creatinine)
Lactic acidosis (rare metabolic complication)
Liver-related abnormalities (monitor liver function in chronic HBV)
Advice: Consult your doctor if any side effects persist or worsen.
Precautions and Warnings
Avoid use if allergic to Tenofovir or any excipients.
Pregnancy and breastfeeding: Use only under medical supervision.
Regular liver and kidney monitoring is recommended during long-term therapy.
Patients should avoid abrupt discontinuation to prevent viral rebound or resistance.
Inform your doctor about all other medications, including supplements, to avoid drug interactions.
Drug Interactions
Other antiretrovirals: May require dose adjustments in combination therapy.
Nephrotoxic drugs: Concurrent use may increase kidney-related side effects.
Drugs affecting liver metabolism: May alter Tenofovir levels; medical guidance is required.
Always inform your healthcare provider before adding new medications.
Storage Instructions
Store at room temperature (below 25°C) in a dry, dark place.
Protect from moisture and direct sunlight.
Keep out of reach of children.
Do not use after the expiry date.
Why Choose TELAVINCE AF25 from Steris Healthcare Pvt. Ltd.?
Steris Healthcare Pvt. Ltd. is a trusted pharmaceutical company delivering high-quality, safe, and affordable medicines. Choosing TELAVINCE AF25 provides:
WHO-GMP Certified Manufacturing: Guaranteed safety and quality.
Effective Viral Suppression: Clinically proven Tenofovir Alafenamide formulation.
Reduced Side Effects: Safer profile for kidney and bone health.
Nationwide Availability: Easily accessible across India.
Patient-Centric Support: Guidance for safe, effective therapy.
Conclusion
Tenofovir Alafenamide 25 mg is a modern, safe, and effective antiviral medication for patients managing chronic Hepatitis B or HIV-1 infection. Its high intracellular potency, reduced systemic exposure, and once-daily dosing make it an ideal choice for long-term therapy. Manufactured by Steris Healthcare Pvt. Ltd., TELAVINCE AF25 ensures patients receive trusted quality, clinical efficacy, and improved safety, supporting a healthier and more confident life.
FAQs
Q1. Can TELAVINCE AF25 cure Hepatitis B?
A1. No, it helps control viral replication, reduce liver damage, and maintain health, but it does not cure the infection.
Q2. How long before I see results?
A2. Significant viral load reduction is usually observed within 4–12 weeks, depending on the individual.
Q3. Can it be taken with food?
A3. Yes, it can be taken with or without food for convenience.
Q4. Is it safe for long-term use?
A4. Yes, with regular monitoring of kidney and liver function, TELAVINCE AF25 is safe for long-term therapy.
